Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers

• Status: Completed
• Trial end date: 2019-07-30
• Target enrollment: 0
• Participant gender: Male

Summary

This is a dose block-randomized, double-blind, placebo- and active-controlled, single and multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of DWP16001 after oral administration in healthy male volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Daewoong Pharmaceutical Co. LTD.
• Treatments: Dapagliflozin

Criteria

Inclusion Criteria:

1. Healthy male adults aged 19 to 50 at the time of screening test.

2. Body weight between 50.0 kg and 90.0 kg and Body Mass Index (BMI) between 18.0 and 27.0.

3. Written consent on voluntary decision of participation prior to the screening procedure after being fully informed of and completely understanding this study.

4. Eligible to participate in the study by discretion of the investigator following medical examination by interview, physical examination, and clinical examination.

Exclusion Criteria:

1. Presence of a clinically significant hepatic, renal, nervous, respiratory, endocrine, blood•tumor, cardiovascular, urogenital, psychiatric disorder or prior history.

2. Presence or prior history of a gastrointestinal disorder (e.g., gastrointestinal ulcers, gastritis, stomach cramps, gastroesophageal reflux disease, Crohn's disease, etc.), or prior history of surgery (except for simple appendectomy or hernia surgery) that may affect safety and PK/PD assessment.

3. Hypersensitivity to a drug containing an ingredient of the investigational product (DWP16001), Dapagliflozin or similar ingredient or other drugs (e.g., aspirin, antibiotics, etc.) or medical history of clinically significant hypersensitivity.

4. Following laboratory abnormalities identified during the screening test:

• AST (SGOT), ALT (SGPT) >1.5 upper limit of normal range

• Creatinine clearance calculated by the MDRD equation < 90 mL/min

• Repeatedly confirmed QTc interval > 450 ms

• Fasting serum glucose > 110mg/dL or < 70mg/dL

• Serum HbA1c > 6.5 mg/dL